

# SITUATION REPORT

# **Nigeria Centre for Disease Control and Prevention**

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDCgov Fi 💆 🖸

TITLE:	UPDATE ON MPOX (MPX) IN NIGERIA
SERIAL NUMBER:	15
EPI-WEEK:	15
DATE:	April 16, 2023

## **Table 1 – Key Indicators**

Reporting Year	Reporting week	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023 Current	Week 15	26	1	0	0.0	1	1
2023 Cumulative	Week 15	574	71	2	3.0	18 +FCT	51
2022 Cumulative	Week 15	42	14	0	0.0	6 + FCT	8

### **Highlights**

- In week 15, the number of new suspected cases is 26, same as 26 cases reported in week 14, 2023. These were reported from fourteen (14) states and FCT-Imo (5), Nasarawa (3), Ogun (3), Bayelsa (3), Anambra (2), Enugu (2), Kano (1), Cross River (1), Katsina (1), Benue (1), Kaduna (1), Zamfara (1), FCT (1), Akwa Ibom (1) and Lagos (1) across 20 Local Government Areas.
- Since week 1 of 2023, eighteen (18) states and FCT have recorded at least one confirmed Mpox case across fifty-one (51) Local Government Areas. In 2023, the States with the highest burden are Lagos (31.0%), Ogun (12.7%), Abia (8.5%), Imo (5.6%) and Edo (5.6%), contributing 62.9% of confirmed
- The number of confirmed cases is One (1) in week 15, 2023, compared with Zero (0) confirmed cases reported in week 15, 2023.
- No death was recorded in week 15, with a CFR of 0.0% same as CFR of 0.0% that was reported in week 14, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 3208 suspected cases have been reported from 36 states and FCT in the country. Of these 3208 suspected cases, 1059 (33.0%) were confirmed (with males predominantly affected) from 34 states and FCT. seventeen (17) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues to coordinate the response activities at all levels.






















Figure 1: Epidemic curve of suspected and confirmed Mpox cases January 2023 till date.




Figure 2: Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date.






















Figure 3: Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date.

Figure 4: Area chart for States showing the trend in suspected and confirmed Mpox cases in highest burden States from January 2023 till date.




Figure 5: Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 16<sup>th</sup> April 2023.



















**Table 1:** Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 – 16<sup>th</sup> April 2023

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023	574	71	2	3.0	18 +FCT	51
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

**Table 2:** Age distribution of cumulative number of confirmed Mpox cases September 2017 – 16<sup>th</sup> April 2023

Age Group	2017	2018	2019	2020	2021	2022	2023	Total
0-10 Years	7	5	1	0	1	125	8	147
11-20 Years	12	4	1	0	4	123	6	150
21-30 Years	34	13	13	4	10	187	22	283
31- 40 Years	26	17	22	4	13	205	17	304
41-50 Years	9	10	9	0	5	89	14	136
> 50 Years	0	0	1	0	1	33	4	39
Total	88	49	47	8	34	762	71	1059















**Table 3:** Nigeria confirmed Mpox cases by State, September 2017 – 16<sup>th</sup> April 2023

S/N	State	2017	2018	2019	2020	2021	2022	2023	Total
1	Lagos	4	1	15	4	6	188	22	240
2	Rivers	25	14	7	1	5	37	3	92
3	Bayelsa	19	11	7	0	6	45	2	90
4	Abia	1	2	0	0	0	58	6	67
5	Delta	3	6	10	1	9	31	1	61
6	Imo	5	2	1	0	0	45	4	57
7	Ogun	0	0	0	0	1	40	9	50
8	Ondo	0	0	0	0	0	40	1	41
9	Edo	4	1	1	0	4	27	4	41
10	FCT	5	0	0	0	1	25	3	34
11	Anambra	0	1	1	0	0	25	0	27
12	Cross River	9	3	1	0	1	12	1	27
13	Kwara	0	0	0	0	0	21	0	21
14	Plateau	0	2	0	1	0	16	0	19
15	Akwa Ibom	6	0	1	0	0	12	3	22
16	Nasarawa	1	1	0	0	0	17	1	20
17	Adamawa	0	0	0	0	0	16	0	16
18	Oyo	1	3	2	0	0	10	1	17
19	Kaduna	0	0	0	0	0	15	2	17
20	Ebonyi	0	0	0	1	0	12	0	13
21	Benue	2	0	0	0	0	10	0	12
22	Borno	0	0	0	0	0	11	2	13
23	Enugu	1	2	1	0	0	4	3	11
24	Katsina	0	0	0	0	0	8	0	8
25	Taraba	0	0	0	0	0	7	0	7
26	Kano	0	0	0	0	0	7	0	7
27	Gombe	0	0	0	0	0	6	0	6
28	Kogi	0	0	0	0	0	5	2	7
29	Osun	0	0	0	0	0	5	0	5
30	Ekiti	2	0	0	0	0	1	0	3
31	Niger Kebbi	0	0	0	0	1	1	1	3
32 33	Bauchi	0	0	0	0	0	2	0	2
34	Zamfara	0	0	0	0	0	1	0	1
35	Yobe	0	0	0	0	0	1	0	1
	Grand Total	88	49	47	8	34	762	71	1059

# **Response activities**

Pillar	Activities to date	Next steps			
Coordination	<ul> <li>Identification of challenges in the control and management of Mpox across all reporting states</li> <li>Weekly situation report development</li> <li>Provide subnational support to states on all Mpox activities</li> </ul>	<ul> <li>Map new stakeholders for Mpox based on needs assessment</li> <li>Hold a facilitators debrief meeting before deployment of staff to the field</li> </ul>			



















Surveillance	<ul> <li>Data cleaning and analysis of Mpox data following harmaonization between surveillance, laboratory and case management pillars</li> <li>Support weekly situation report development</li> <li>Follow up with all reporting states on variable completeness and contact</li> </ul>	<ul> <li>Offsite support to data managers and surveillance notification officers on Mpox reporting tools</li> </ul>
	information on SORMAS	
Laboratory	<ul> <li>Ensure proper testing of Mpox samples according to international standards</li> <li>Provide offsites support to all states on appropriate sample collection, transportation and management</li> <li>44% of samples met overall turnaround from NRL (time sample collected from states to time result shared to states)</li> </ul>	Conduct training of States on Mpox Sample management

#### Notes on this report.

#### **Data Source**

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

#### **Case definitions**

#### Suspected case

An acute illness with fever >38.3°C, intense headache, lymphadenopathy, back pain, myalgia, and
intense asthenia followed one to three days later by a progressively developing rash often beginning
on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms
of the hand.

#### Probable case

• A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case.

#### Confirmed case.

A clinically compatible case that is laboratory confirmed

#### Contact

 Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

#### **Calculations**

• Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.

















